Kite Pharma (NASDAQ: KITE) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Kite Pharma to related companies based on the strength of its analyst recommendations, profitability, risk, dividends, valuation, earnings and institutional ownership.
This is a summary of recent ratings for Kite Pharma and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Kite Pharma Competitors||863||3213||11661||232||2.71|
Earnings & Valuation
This table compares Kite Pharma and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Kite Pharma Competitors||$284.28 million||$33.78 million||83.22|
Kite Pharma’s peers have higher revenue and earnings than Kite Pharma. Kite Pharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
87.7% of Kite Pharma shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 14.0% of Kite Pharma shares are held by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Kite Pharma and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Kite Pharma Competitors||-5,311.45%||-218.34%||-39.53%|
Kite Pharma peers beat Kite Pharma on 7 of the 10 factors compared.
About Kite Pharma
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).
Receive News & Ratings for Kite Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma and related companies with MarketBeat.com's FREE daily email newsletter.